The US Food and Drug Administration (USFDA) had conducted a post approval and GMP inspection of company's small molecules API manufacturing facility at Biocon campus in Bengaluru from February 20 ...
February 1, 2025 India's Biocon plans IPO for biosimilars business by March 2026 Indian biopharmaceutical firm Biocon is likely to list its key biosimilars business by March 2026 and aims for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback